Cost relief may be coming for Medicare recipients who use insulin. But a proposed $35 monthly cap for those with private insurance is no longer part of the Senate’s Inflation Relief Act, which goes before the House on Friday.

The cost of insulin, which is used by people with diabetes to control their blood sugar, has become a political issue, with politicians like Vermont Sen. Bernie Sanders decrying how much Americans pay compared to people in other countries.

High drug and health care costs continue to prevent millions of Americans from achieving full health. Nearly 1 in 2 American adults report difficulty affording health care costs. It’s no wonder that voters consistently rank bringing down prescription drug prices and other measures to reduce the cost of care as among Congress’ top priorities.

Medicare is poised to renegotiate the prices of some of its most expensive drugs through a historic expansion of its power, which could reduce costs for many seniors as well as federal spending on its prescription drug plan.

The changes are tucked inside a massive spending-and-tax bill in Congress that includes $433 billion in investments in health-care and clean energy. House Democrats passed the Inflation Reduction Act on Friday in a 220 to 207 vote along party lines, ending a tortured legislative process that took more than a year.